NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Natural Killer Cell Combination Immunotherapy with Durable, Complete Response Data and 78% Disease Control in Refractory Triple Negative Breast Cancer at SABCS

World’s first combination of off-the-shelf NK with checkpoint inhibitor plus antigen simulation via adenovirus to induce immune system activation Ongoing durable complete responses ranging from 8 to 11 months observed in TNBC patients who failed standard of care...